Success Metrics

Clinical Success Rate
90.5%

Based on 38 completed trials

Completion Rate
90%(38/42)
Active Trials
3(6%)
Results Posted
45%(17 trials)
Terminated
4(8%)

Phase Distribution

Ph phase_4
22
42%
Ph phase_2
3
6%
Ph not_applicable
9
17%
Ph phase_3
5
10%
Ph phase_1
6
12%

Phase Distribution

6

Early Stage

3

Mid Stage

27

Late Stage

Phase Distribution45 total trials
Phase 1Safety & dosage
6(13.3%)
Phase 2Efficacy & side effects
3(6.7%)
Phase 3Large-scale testing
5(11.1%)
Phase 4Post-market surveillance
22(48.9%)
N/ANon-phased studies
9(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.5%

38 of 42 finished

Non-Completion Rate

9.5%

4 ended early

Currently Active

3

trials recruiting

Total Trials

52

all time

Status Distribution
Active(3)
Completed(38)
Terminated(4)
Other(7)

Detailed Status

Completed38
unknown7
Terminated4
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
52
Active
3
Success Rate
90.5%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (13.3%)
Phase 23 (6.7%)
Phase 35 (11.1%)
Phase 422 (48.9%)
N/A9 (20.0%)

Trials by Status

terminated48%
completed3873%
unknown713%
recruiting36%

Recent Activity

Clinical Trials (52)

Showing 20 of 52 trialsScroll for more
NCT01530373Phase 2

Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

Recruiting
NCT07312955Not Applicable

Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in Females

Completed
NCT06551246Phase 3

Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)

Recruiting
NCT06465576Phase 4

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Recruiting
NCT06489951Not Applicable

Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker

Completed
NCT07114848Phase 4

Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.

Completed
NCT01093534Phase 4

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

Completed
NCT03602508

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed
NCT03149809Phase 3

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Completed
NCT04023253Phase 3

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Unknown
NCT04437108Not Applicable

Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO

Completed
NCT02540707Phase 4

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Completed
NCT00852696Not Applicable

Over Active Bladder Patients Having Sling Surgery

Terminated
NCT03787654Not Applicable

Electroacupuncture and Solifenacin for Urgency-predominant Mixed Urinary Incontinence

Unknown
NCT03572231

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed
NCT01559389Phase 4

Incontinence & Intimate Partners: Assessing the Contribution of Treatment

Completed
NCT02047032Not Applicable

Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence

Completed
NCT01767519Phase 3

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Completed
NCT02549196Phase 2

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

Completed
NCT01457573Phase 4

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

Completed

Drug Details

Intervention Type
DRUG
Total Trials
52